Viracta Therapeutics, Inc.
VIRXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001061027
Viracta Therapeutics, Inc. was delisted in 2025; its insiders filed their last Form 4 on Nov 27, 2024; 32 institutions reported holding it in 13F filings for Q4 2024, worth $583.0K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Viracta Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Viracta Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Royston Ivor | Director | 839,741 | Nov 27, 2024 | 0 |
| Pomerantz Roger | Director | 126,478 | Nov 27, 2024 | 0 |
| Darcy Thomas E | Director | – | Jun 24, 2024 | 0 |
| Simon Barry J. | Director | – | Jun 24, 2024 | 0 |
| Barlow Jane F | Director | – | Jun 24, 2024 | 0 |
| Murphy Samuel Lafayette | Director | – | Jun 24, 2024 | 0 |
| Rubino Stephen | Director | – | Jun 24, 2024 | 0 |
| Borellini Flavia | Director | – | Jun 24, 2024 | 0 |
| Chung Jane | Director | – | Jun 24, 2024 | 0 |
| Faerm Michael E. | Chief Financial Officer | – | May 16, 2024 | 0 |
| Rothera Mark | President and CEO | 100,000 | Mar 13, 2024 | 0 |
| Chevallard Daniel R. | CFO and COO | 102,306 | Mar 13, 2024 | 0 |
| Cohen Darrel P. | Chief Medical Officer | – | Mar 13, 2024 | 0 |
| Rojkjaer Lisa | Chief Medical Officer | 48,087 | Mar 17, 2023 | 0 |
| Onetto Nicole | Director | – | Jun 10, 2022 | 0 |
| Huang Michael | Director | – | Jun 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 (view filing) | Feb 27 | Same day | Chevallard Daniel R.CFO and COO | SSale | −3.40K | $0.73 | −$2.49K | −3.2%102.3K after | |
| Dec 4, 2023 (view filing)4:54 PM ET | Nov 30-Dec 1 | 4 days | Rothera MarkPresident and CEO | PPurchase | +100.0K | $0.4936 | +$49.4K | New position100.0K after | 2 lots |
| Nov 28, 2023 (view filing) | Nov 28 | Same day | Chevallard Daniel R.CFO and COO | SSale | −3.72K | $0.50 | −$1.86K | −3.6%98.8K after | |
| Aug 29, 2023 (view filing) | Aug 28 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.51K | $1.45 | −$5.09K | −3.5%95.7K after | |
| May 26, 2023 (view filing) | May 25 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.63K | $1.42 | −$5.16K | −3.8%92.3K after | |
| Feb 28, 2023 (view filing) | Feb 27 | 1 day | Rojkjaer LisaChief Medical Officer | SSale | −2.16K | $1.68 | −$3.62K | −4.3%48.1K after | |
| Feb 28, 2023 (view filing) | Feb 27 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.60K | $1.68 | −$6.05K | −3.9%89.0K after | |
| Nov 29, 2022 (view filing) | Nov 28 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.53K | $2.72 | −$9.61K | −4.0%85.7K after | |
| Nov 29, 2022 (view filing) | Nov 28 | 1 day | Rojkjaer LisaChief Medical Officer | SSale | −2.12K | $2.72 | −$5.76K | −4.4%46.1K after | |
| Aug 29, 2022 (view filing) | Aug 26 | 3 days | Rojkjaer LisaChief Medical Officer | SSale | −2.19K | $4.01 | −$8.78K | −4.7%44.1K after | |
| Aug 29, 2022 (view filing) | Aug 26 | 3 days | Chevallard Daniel R.CFO and COO | SSale | −3.65K | $4.02 | −$14.7K | −4.2%82.4K after | |
| Aug 29, 2022 (view filing) | Aug 26 | 3 days | Royston IvorCEO & President | SSale | −13.4K | $4.01 | −$53.6K | −2.1%612.8K after | |
| May 27, 2022 (view filing) | May 26 | 1 day | Royston IvorCEO & President | SSale | −13.2K | $1.90 | −$25.0K | −2.1%600.9K after | |
| May 27, 2022 (view filing) | May 26 | 1 day | Rojkjaer LisaChief Medical Officer | SSale | −2.15K | $1.90 | −$4.09K | −4.9%42.2K after | |
| May 27, 2022 (view filing) | May 26 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.60K | $1.90 | −$6.83K | −4.3%79.1K after | |
| Mar 1, 2022 (view filing) | Feb 28 | 1 day | Royston IvorCEO & President | SSale | −14.6K | $2.78 | −$40.7K | −2.4%588.9K after | |
| Mar 1, 2022 (view filing) | Feb 28 | 1 day | Rojkjaer LisaChief Medical Officer | SSale | −2.40K | $2.78 | −$6.66K | −5.6%40.2K after | |
| Mar 1, 2022 (view filing) | Feb 28 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −4.00K | $2.78 | −$11.1K | −5.0%75.8K after | |
| Nov 29, 2021 (view filing)7:48 PM ET | Nov 26-29 | 3 days | Chevallard Daniel R.CFO and COO | SSale | −7.58K | $4.81 | −$36.5K | −9.4%73.0K after | 2 lots |
| Nov 29, 2021 (view filing)7:46 PM ET | Nov 26-29 | 3 days | Royston IvorCEO & President | SSale | −27.7K | $4.81 | −$133.5K | −4.6%571.3K after | 2 lots |
| Nov 29, 2021 (view filing) | Nov 26-29 | 3 days | Rojkjaer LisaChief Medical Officer | SSale | −4.54K | $4.81 | −$21.8K | −10.6%38.5K after | 2 lots |
| Nov 15, 2021 (view filing) | Nov 15 | Same day | Royston IvorCEO & President | PPurchase | +8.00K | $5.56 | +$44.5K | +1.5%548.6K after |